Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Tammie C, Yeh"'
Autor:
Huawei Chen, Edwin Clark, Michael Zinda, Michael J. Waring, Stephen E. Fawell, Gordon B. Mills, Paul Lyne, Corinne Reimer, Jonathan R. Dry, Alfred A. Rabow, Tammie C. Yeh, Greg O'Connor, Graeme Walker, Miika J. Ahdesmaki, Larry Bao, Michael Collins, Deborah Lawson, Lillian Castriotta, Shenghua Wen, Jingwen Zhang, Tony Cheung, Scott Boiko, Ian L. Dale, Philip Petteruti, Wenxian Wang, Austin Dulak, Yi Yao, Maureen M. Hattersley, Garrett W. Rhyasen
Supplementary Figure 1. AZD5153 shows reduced BRD4 binding activity when BD2 function is abolished; Supplementary Figure 2. AZD5153 modulates MYC protein levels across hematologic cancer cell lines; Supplementary Figure 3. Gene Ontology (GO) analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50a3fc1c9e0ac7cc5baf19a1c1e82cb3
https://doi.org/10.1158/1535-7163.22506301
https://doi.org/10.1158/1535-7163.22506301
Autor:
Huawei Chen, Edwin Clark, Michael Zinda, Michael J. Waring, Stephen E. Fawell, Gordon B. Mills, Paul Lyne, Corinne Reimer, Jonathan R. Dry, Alfred A. Rabow, Tammie C. Yeh, Greg O'Connor, Graeme Walker, Miika J. Ahdesmaki, Larry Bao, Michael Collins, Deborah Lawson, Lillian Castriotta, Shenghua Wen, Jingwen Zhang, Tony Cheung, Scott Boiko, Ian L. Dale, Philip Petteruti, Wenxian Wang, Austin Dulak, Yi Yao, Maureen M. Hattersley, Garrett W. Rhyasen
Protein modulation by AZD5153 in hematological cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d95847a4372d50fae63c38140fe63041
https://doi.org/10.1158/1535-7163.22506292.v1
https://doi.org/10.1158/1535-7163.22506292.v1
Autor:
Huawei Chen, Edwin Clark, Michael Zinda, Michael J. Waring, Stephen E. Fawell, Gordon B. Mills, Paul Lyne, Corinne Reimer, Jonathan R. Dry, Alfred A. Rabow, Tammie C. Yeh, Greg O'Connor, Graeme Walker, Miika J. Ahdesmaki, Larry Bao, Michael Collins, Deborah Lawson, Lillian Castriotta, Shenghua Wen, Jingwen Zhang, Tony Cheung, Scott Boiko, Ian L. Dale, Philip Petteruti, Wenxian Wang, Austin Dulak, Yi Yao, Maureen M. Hattersley, Garrett W. Rhyasen
Cell line authentication information
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ff0443ca83bc32e2d5b91ded374d6cf
https://doi.org/10.1158/1535-7163.22506298.v1
https://doi.org/10.1158/1535-7163.22506298.v1
Autor:
Huawei Chen, Edwin Clark, Michael Zinda, Michael J. Waring, Stephen E. Fawell, Gordon B. Mills, Paul Lyne, Corinne Reimer, Jonathan R. Dry, Alfred A. Rabow, Tammie C. Yeh, Greg O'Connor, Graeme Walker, Miika J. Ahdesmaki, Larry Bao, Michael Collins, Deborah Lawson, Lillian Castriotta, Shenghua Wen, Jingwen Zhang, Tony Cheung, Scott Boiko, Ian L. Dale, Philip Petteruti, Wenxian Wang, Austin Dulak, Yi Yao, Maureen M. Hattersley, Garrett W. Rhyasen
The bromodomain and extraterminal (BET) protein BRD4 regulates gene expression via recruitment of transcriptional regulatory complexes to acetylated chromatin. Pharmacological targeting of BRD4 bromodomains by small molecule inhibitors has proven to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::491aac7aed6ce358594bc45ec314c59a
https://doi.org/10.1158/1535-7163.c.6538351.v1
https://doi.org/10.1158/1535-7163.c.6538351.v1
Autor:
Huawei Chen, Edwin Clark, Michael Zinda, Michael J. Waring, Stephen E. Fawell, Gordon B. Mills, Paul Lyne, Corinne Reimer, Jonathan R. Dry, Alfred A. Rabow, Tammie C. Yeh, Greg O'Connor, Graeme Walker, Miika J. Ahdesmaki, Larry Bao, Michael Collins, Deborah Lawson, Lillian Castriotta, Shenghua Wen, Jingwen Zhang, Tony Cheung, Scott Boiko, Ian L. Dale, Philip Petteruti, Wenxian Wang, Austin Dulak, Yi Yao, Maureen M. Hattersley, Garrett W. Rhyasen
Differentially expressed genes with AZD5153 treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1840bcd6939c18a3d1c667350d651fff
https://doi.org/10.1158/1535-7163.22506295
https://doi.org/10.1158/1535-7163.22506295
Autor:
Huawei Chen, J. Carl Barrett, Maureen Hattersley, Austin Dulak, Philip Petteruti, Greg O'Connor, Tammie C. Yeh
Purpose: AZD5153 is a novel BRD4/BET inhibitor with a distinctive bivalent bromodomain binding mode. To support its clinical development, we identified pharmacodynamic (PD) biomarkers for use in clinical trials to establish target engagement.Experime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fb93b1f92955ec9025ffe2549c19285
https://doi.org/10.1158/1078-0432.c.6526124
https://doi.org/10.1158/1078-0432.c.6526124
Autor:
Eli Wallace, Kevin Koch, James D. Winkler, Patrice A. Lee, Joe Lyssikatos, Brian Hurley, Allison Marlow, Stefan Gross, Barbara J. Brandhuber, Darin Smith, Janet Parry, Ron J. Evans, Heidi Colwell, Josh Ballard, Bryan A. Bernat, Vivienne Marsh, Tammie C. Yeh
Supplementary Data, Yeh, et al. from Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cb220f9585897004967629e2407f636
https://doi.org/10.1158/1078-0432.22441213.v1
https://doi.org/10.1158/1078-0432.22441213.v1
Autor:
Huawei Chen, J. Carl Barrett, Maureen Hattersley, Austin Dulak, Philip Petteruti, Greg O'Connor, Tammie C. Yeh
Figure S1: Downregulation of CCR2, CD180, MYC and upregulation of HEXIM1 mRNAs by AZD5153 in cells can be detected at 4h; Figure S2: Other BRD4/BET compounds can also downregulate CCR2 and CD180 mRNAs in hematological tumor cell lines; Supplementary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::317d92c5b696a9e5ac20538f597c269d
https://doi.org/10.1158/1078-0432.22465697.v1
https://doi.org/10.1158/1078-0432.22465697.v1
Autor:
Eli Wallace, Kevin Koch, James D. Winkler, Patrice A. Lee, Joe Lyssikatos, Brian Hurley, Allison Marlow, Stefan Gross, Barbara J. Brandhuber, Darin Smith, Janet Parry, Ron J. Evans, Heidi Colwell, Josh Ballard, Bryan A. Bernat, Vivienne Marsh, Tammie C. Yeh
Purpose: The Ras-Raf-mitogen-activated protein kinase kinase (MEK) pathway is overactive in many human cancers and is thus a target for novel therapeutics. We have developed a highly potent and selective inhibitor of MEK1/2. The purpose of these stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::406a4a31b0cf89e0543cd3f66dfd4a9e
https://doi.org/10.1158/1078-0432.c.6518341.v1
https://doi.org/10.1158/1078-0432.c.6518341.v1
Autor:
Prasanthi Geda, Mark A. McCoy, Liping Yang, Chaomin Li, Armetta D. Hill, Xavier Fradera, Marianne L. Spatz, Matthew Ernst Voss, Carolyn Michele Cammarano, Pierre Daublain, Xiao Wang, Christopher F. Thompson, B. Wesley Trotter, C. Gary Marshall, Michael H. Reutershan, Peter Goldenblatt, Latha G. Nair, Manami Shizuka, Tammie C. Yeh, John G. Cryan, Isabelle Dussault, Michelle Martinez, Mingmei Cai, Raymond A. Kemper, Binyuan Sun, Michelle R. Machacek, Dietrich Steinhuebel, Giovanna Scapin, Michael D. Altman, Stephane L. Bogen, Matthew Christopher, Dapeng Chen, Victoria Kutilek, Weidong Pan
Publikováno v:
Journal of Medicinal Chemistry. 64:16213-16241
Identification of low-dose, low-molecular-weight, drug-like inhibitors of protein-protein interactions (PPIs) is a challenging area of research. Despite the challenges, the therapeutic potential of PPI inhibition has driven significant efforts toward
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9f003ba884dc7f950fc132b2a33cadf
https://doi.org/10.1021/acs.jmedchem.1c01524
https://doi.org/10.1021/acs.jmedchem.1c01524
